REG - ReNeuron Group plc - Alliance for Regenerative Medicine presentation

ReNeuronAnnouncement

18/03/2019 12:00

RNS Number : 1790T
ReNeuron Group plc
18 March 2019
 


 



18 March 2019


AIM: RENE



 
ReNeuron Group plc
("ReNeuron" or the "Company")
 
ReNeuron to Present at the Alliance for Regenerative Medicine's
Cell & Gene Therapy Investor Day
 
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announced that Olav Hellebø, the Company's Chief Executive Officer, will present at the Alliance for Regenerative Medicine's Cell & Gene Therapy Investor Day on Thursday, March 21, 2019 at 9:10 am ET (13:10 pm GMT) at The Metropolitan Club in New York City.
A live and archived webcast of the presentation will be available on the Webcasts & Presentations page of the Company's website at www.reneuron.com.
 
 
ENDS
 
ENQUIRIES:
 



ReNeuron


+44 (0)20 3819 8400




Olav Hellebø, Chief Executive Officer








Michael Hunt, Chief Financial Officer








Buchanan


+44 (0) 20 7466 5000




Mark Court, Sophie Wills, Tilly Abraham








Argot Partners








Stephanie Marks, Claudia Styslinger


+ 00 1 212 600 1902




Stifel Nicolaus Europe Limited


+44 (0) 20 7710 7600




Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)








Nplus1 Singer Advisory LLP


+44 (0) 20 7496 3000




Mark Taylor (Joint Broker)







 
 
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.
 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCBBGDXCSBBGCI